BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 17908926)

  • 21. The molecular functions of common and atypical MLL fusion protein complexes.
    Takahashi S; Yokoyama A
    Biochim Biophys Acta Gene Regul Mech; 2020 Jul; 1863(7):194548. PubMed ID: 32320750
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Functional characterisation of different MLL fusion proteins by using inducible Sleeping Beauty vectors.
    Wächter K; Kowarz E; Marschalek R
    Cancer Lett; 2014 Oct; 352(2):196-202. PubMed ID: 25016062
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Malignant hematopoietic cell lines: in vitro models for the study of MLL gene alterations.
    Drexler HG; Quentmeier H; MacLeod RA
    Leukemia; 2004 Feb; 18(2):227-32. PubMed ID: 14671638
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ECSASB2 mediates MLL degradation during hematopoietic differentiation.
    Wang J; Muntean AG; Hess JL
    Blood; 2012 Feb; 119(5):1151-61. PubMed ID: 22174154
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interaction of AF4 wild-type and AF4.MLL fusion protein with SIAH proteins: indication for t(4;11) pathobiology?
    Bursen A; Moritz S; Gaussmann A; Moritz S; Dingermann T; Marschalek R
    Oncogene; 2004 Aug; 23(37):6237-49. PubMed ID: 15221006
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of CBL, a proto-oncogene at 11q23.3, as a novel MLL fusion partner in a patient with de novo acute myeloid leukemia.
    Fu JF; Hsu JJ; Tang TC; Shih LY
    Genes Chromosomes Cancer; 2003 Jun; 37(2):214-9. PubMed ID: 12696071
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The reciprocal world of MLL fusions: A personal view.
    Marschalek R
    Biochim Biophys Acta Gene Regul Mech; 2020 Jul; 1863(7):194547. PubMed ID: 32294539
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MLL-ENL-mediated leukemia initiation at the interface of lymphoid commitment.
    Ugale A; Säwén P; Dudenhöffer-Pfeifer M; Wahlestedt M; Norddahl GL; Bryder D
    Oncogene; 2017 Jun; 36(22):3207-3212. PubMed ID: 28068328
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The small oligomerization domain of gephyrin converts MLL to an oncogene.
    Eguchi M; Eguchi-Ishimae M; Greaves M
    Blood; 2004 May; 103(10):3876-82. PubMed ID: 14751928
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Functional diversity of inhibitors tackling the differentiation blockage of MLL-rearranged leukemia.
    Brzezinka K; Nevedomskaya E; Lesche R; Steckel M; Eheim AL; Haegebarth A; Stresemann C
    J Hematol Oncol; 2019 Jun; 12(1):66. PubMed ID: 31253180
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A carboxy-terminal domain of ELL is required and sufficient for immortalization of myeloid progenitors by MLL-ELL.
    DiMartino JF; Miller T; Ayton PM; Landewe T; Hess JL; Cleary ML; Shilatifard A
    Blood; 2000 Dec; 96(12):3887-93. PubMed ID: 11090074
    [TBL] [Abstract][Full Text] [Related]  

  • 32. AF4 and AF4-MLL mediate transcriptional elongation of 5-lipoxygenase mRNA by 1, 25-dihydroxyvitamin D3.
    Ahmad K; Scholz B; Capelo R; Schweighöfer I; Kahnt AS; Marschalek R; Steinhilber D
    Oncotarget; 2015 Sep; 6(28):25784-800. PubMed ID: 26329759
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Functional inactivation of P53 as a potential mechanism of MLL leukemogenesis.
    Wiederschain D; Yuan ZM
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2006 Oct; 31(5):617-20. PubMed ID: 17062917
    [TBL] [Abstract][Full Text] [Related]  

  • 34. NUP98-MLL fusion in human acute myeloblastic leukemia.
    Kaltenbach S; Soler G; Barin C; Gervais C; Bernard OA; Penard-Lacronique V; Romana SP
    Blood; 2010 Sep; 116(13):2332-5. PubMed ID: 20558618
    [TBL] [Abstract][Full Text] [Related]  

  • 35.
    Britten O; Ragusa D; Tosi S; Kamel YM
    Cells; 2019 Oct; 8(11):. PubMed ID: 31671855
    [TBL] [Abstract][Full Text] [Related]  

  • 36. circRNA circAF4 functions as an oncogene to regulate MLL-AF4 fusion protein expression and inhibit MLL leukemia progression.
    Huang W; Fang K; Chen TQ; Zeng ZC; Sun YM; Han C; Sun LY; Chen ZH; Yang QQ; Pan Q; Luo XQ; Wang WT; Chen YQ
    J Hematol Oncol; 2019 Oct; 12(1):103. PubMed ID: 31623653
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hematopoietic transformation in the absence of MLL1/KMT2A: distinctions in target gene reactivation.
    Chen Y; Ernst P
    Cell Cycle; 2019 Jul; 18(14):1525-1531. PubMed ID: 31161857
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Don't skip the G1 phase: how APC/CCdh1 keeps SCFSKP2 in check.
    Bashir T; Pagano M
    Cell Cycle; 2004 Jul; 3(7):850-2. PubMed ID: 15190201
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of embryonic and adult leukemia mouse models driven by MLL-ENL translocation.
    Sinha R; Porcheri C; d'Altri T; González J; Ruiz-Herguido C; Rabbitts T; Espinosa L; Bigas A
    Exp Hematol; 2020 May; 85():13-19. PubMed ID: 32437911
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins.
    Ayton PM; Cleary ML
    Oncogene; 2001 Sep; 20(40):5695-707. PubMed ID: 11607819
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.